We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Device Improves Safety and Accuracy of Capillary Blood Collection

By LabMedica International staff writers
Posted on 12 Feb 2010
A newly launched device improves the safety, accuracy, and turnaround time of capillary blood collection and testing in patients with fragile veins that can be difficult to access, such as infants, children, oncology patients, and the elderly.

The preanalytical phase is a critical step in the diagnostic process, with significant impact to patient health, healthcare worker safety, and workflow efficiencies. More...
Historically, low-volume capillary blood collection has increased test result turnaround time due to incompatibility with automated testing instruments and a higher risk of patient identification errors. The new product is fully compatible with most automated hematology instruments, reducing turnaround time and costs associated with sample transfer and relabeling.

The new BD (Franklin Lakes, NJ, USA) microtainer MAP tube is a low-volume collection system that accommodates standard, full-size patient identification labels. Traditional microcollection tubes are incompatible with standard labels due to their size. This can lead to dangerous labeling errors that can result in misdiagnosis and incorrect patient treatment.

The design of the microtainer MAP tube enables automated processing with 81% less blood than venous systems, improving test turnaround time and laboratory efficiency. This is a critical improvement for patients from whom it is difficult to obtain a sufficient blood sample to perform critical diagnostic tests.

BD is a global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. The company is focused on enhancing the quality and speed of diagnosing infectious diseases and cancers, improving drug delivery, and advancing research, discovery and production of new drugs and vaccines.

Related Links:

BD


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.